Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Welgene Biotech Co.Ltd. (6661) - Total Assets
Latest total assets as of September 2025: NT$554.58 Million TWD
Based on the latest financial reports, Welgene Biotech Co.Ltd. (6661) holds total assets worth NT$554.58 Million TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Welgene Biotech Co.Ltd. - Total Assets Trend (2014–2024)
This chart illustrates how Welgene Biotech Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Welgene Biotech Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Welgene Biotech Co.Ltd.'s total assets of NT$554.58 Million consist of 60.6% current assets and 39.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 32.8% |
| Accounts Receivable | NT$41.01 Million | 7.8% |
| Inventory | NT$36.88 Million | 7.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Welgene Biotech Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Welgene Biotech Co.Ltd.'s current assets represent 60.6% of total assets in 2024, a decrease from 83.2% in 2014.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, down from 43.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 7.8% of total assets.
Welgene Biotech Co.Ltd. Competitors by Total Assets
Key competitors of Welgene Biotech Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Welgene Biotech Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Welgene Biotech Co.Ltd. generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Welgene Biotech Co.Ltd. generates $ 0.21 in net profit.
Welgene Biotech Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 2.63 | 2.76 |
| Quick Ratio | 2.33 | 2.25 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$215.54 Million | NT$ 183.63 Million | NT$ 169.14 Million |
Welgene Biotech Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Welgene Biotech Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.49 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | NT$528.25 Million |
| Market Capitalization | $3.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Welgene Biotech Co.Ltd.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Welgene Biotech Co.Ltd.'s assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Welgene Biotech Co.Ltd. (2014–2024)
The table below shows the annual total assets of Welgene Biotech Co.Ltd. from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$528.25 Million | -3.63% |
| 2023-12-31 | NT$548.16 Million | +25.81% |
| 2022-12-31 | NT$435.71 Million | +2.63% |
| 2021-12-31 | NT$424.54 Million | +17.83% |
| 2020-12-31 | NT$360.29 Million | -14.67% |
| 2019-12-31 | NT$422.25 Million | +16.53% |
| 2018-12-31 | NT$362.34 Million | +16.13% |
| 2017-12-31 | NT$312.00 Million | +13.03% |
| 2016-12-31 | NT$276.03 Million | -1.94% |
| 2015-12-31 | NT$281.50 Million | +26.51% |
| 2014-12-31 | NT$222.51 Million | -- |